Cargando…

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Retraction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037903/ https://www.ncbi.nlm.nih.gov/pubmed/35468166 http://dx.doi.org/10.1371/journal.pone.0267745

Ejemplares similares

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Retraction: Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2015)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

Retraction: The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer
por: Lee, JM, et al.
Publicado: (2014)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Retraction Note: PlncRNA-1 induces apoptosis through the Her-2 pathway in prostate cancer cells
por: Yang, Qing, et al.
Publicado: (2023)

Retracted: Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
por: Markers, Disease
Publicado: (2023)

Retraction: A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells Differentiation
Publicado: (2022)

Retraction of “Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice”
por: Leng, Weibing, et al.
Publicado: (2020)

Retracted: Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Retraction of ‘Functional dissection of the C‐terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani’
por: Sengupta, Tanushri, et al.
Publicado: (2021)

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]
Publicado: (2017)

Retracted: Visualization and Analysis of Mapping Knowledge Domain of Heterogeneous Traffic Flow
por: Intelligence and Neuroscience, Computational
Publicado: (2023)

Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
Publicado: (2022)

Retracted: Caveolin and MAP kinase interaction in angiotensin II preconditioning of the myocardium
por: Das, Manika, et al.
Publicado: (2012)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Retracted: Activation of CD137 Signaling Enhances Vascular Calcification through c-Jun N-Terminal Kinase-Dependent Disruption of Autophagic Flux
por: Inflammation, Mediators of
Publicado: (2022)

Retraction: Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKα-Mediated NF-κB Activation
Publicado: (2019)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

Retraction: DMA, a Bisbenzimidazole, Offers Radioprotection by Promoting NFκB Transactivation through NIK/IKK in Human Glioma Cells
Publicado: (2020)

Nuclear import of prototype foamy virus transactivator Bel1 is mediated by KPNA1, KPNA6 and KPNA7
por: Duan, Jihui, et al.
Publicado: (2017)

Retraction: Aurora kinase-C-T191D is constitutively active mutant
por: Khan, Jabbar, et al.
Publicado: (2012)

Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor
por: Akhtar, Saghir, et al.
Publicado: (2015)

Retracted: Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients—An Integrated Bioinformatics Approach
por: Markers, Disease
Publicado: (2023)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment
por: Parrini, Matthias, et al.
Publicado: (2018)

Retraction: Interferon-β Induces Cellular Senescence in Cutaneous Human Papilloma Virus-Transformed Human Keratinocytes by Affecting p53 Transactivating Activity
Publicado: (2019)

Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
por: Pérez-Martínez, Dayana, et al.
Publicado: (2022)

Retracted: Event Scene Method of Legal Domain Knowledge Map Based on Neural Network Hybrid Model
por: and Biomechanics, Applied Bionics
Publicado: (2022)

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone
por: Williams, Christopher C., et al.
Publicado: (2004)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hpqd0ps3k1m8knm16q9517k48r